Kane Logo Cropped TransBG.png
Kane to Host Investor Webinar – What Kane has in Store for 2025 Including the Acquisition of FB Dermatology
21. Januar 2025 08:30 ET | Kane Biotech Inc.
WINNIPEG, Manitoba, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane”) announces that it will be hosting a webinar on Thursday, January 23, 2025 at 4:15pm Eastern...
Kane Logo Cropped TransBG.png
Kane Biotech Announces First Closing of Private Placement Offering and Extension of Private Placement Offering
20. Januar 2025 08:30 ET | Kane Biotech Inc.
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, Jan. 20, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”,...
Kane Logo Cropped TransBG.png
Kane Biotech Announces $3,000,000 Private Placement Offering
03. Dezember 2024 08:30 ET | Kane Biotech Inc.
WINNIPEG, Manitoba, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces today that it intends to undertake a non-brokered...
Kane Logo Cropped TransBG.png
Kane Biotech Announces Third Quarter 2024 Financial Results
28. November 2024 16:15 ET | Kane Biotech Inc.
WINNIPEG, Manitoba, Nov. 28, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) today announces its third quarter 2024 financial results. ...
Kane Logo Cropped TransBG.png
Kane Biotech Announces Change in US Distribution Partner for revyve™ Antimicrobial Wound Gel
27. November 2024 08:30 ET | Kane Biotech Inc.
WINNIPEG, Manitoba, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company”, “Kane Biotech” or “Kane”) announces today that BioStem Technologies Inc....
Kane Logo Cropped TransBG.png
Kane Biotech to Release Third Quarter 2024 Financial Results on November 28, 2024
21. November 2024 16:30 ET | Kane Biotech Inc.
WINNIPEG, Manitoba, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”) will release its third quarter 2024 financial results after market close on...
Kane Logo Cropped TransBG.png
Kane Biotech Announces Health Canada Approval of revyve™ Antimicrobial Wound Gel
14. November 2024 13:10 ET | Kane Biotech Inc.
WINNIPEG, Manitoba, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces today that it has received Health Canada approval of its...
Kane Logo Cropped TransBG.png
Kane Biotech Provides Investor Update Following FB Dermatology Acquisition Announcement
14. November 2024 08:30 ET | Kane Biotech Inc.
WINNIPEG, Manitoba, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company”, “Kane Biotech”) announces today that President & CEO, Marc Edwards and Dr....
Kane Logo Cropped TransBG.png
Kane Biotech Announces Agreement to Acquire FB Dermatology
12. November 2024 13:08 ET | Kane Biotech Inc.
WINNIPEG, Manitoba, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company”, “Kane Biotech”) announces today that it has entered into a binding term sheet (the...
Kane Logo Cropped TransBG.png
Kane Biotech Announces Donation of revyve™ Antimicrobial Wound Gel to Ukraine
23. Oktober 2024 08:30 ET | Kane Biotech Inc.
WINNIPEG, Manitoba, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it is donating 2,000 ounces of revyve™ Antimicrobial Wound...